Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over…
3,577$
6,77%
Echtzeit-Aktienkurs Exagen Inc.
Bid:
Ask:
Nachrichten zur Exagen Inc. Aktie
Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript
…
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance
CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing…
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference
CARLSBAD, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions,…
Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript
…
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing…
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
Exagen (XGN) delivered earnings and revenue surprises of 52.50% and 9.21%, respectively, for the quarter ended March 2024. Do the…
Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript
…
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions,…
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
Exagen Inc. (XGN) delivered earnings and revenue surprises of 24.39% and 20.40%, respectively, for the quarter ended December 2023. Do…